548 related articles for article (PubMed ID: 26931466)
1. Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy.
Zhao X; Feng Z; Ling KK; Mollin A; Sheedy J; Yeh S; Petruska J; Narasimhan J; Dakka A; Welch EM; Karp G; Chen KS; Metzger F; Ratni H; Lotti F; Tisdale S; Naryshkin NA; Pellizzoni L; Paushkin S; Ko CP; Weetall M
Hum Mol Genet; 2016 May; 25(10):1885-1899. PubMed ID: 26931466
[TBL] [Abstract][Full Text] [Related]
2. Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy.
Naryshkin NA; Weetall M; Dakka A; Narasimhan J; Zhao X; Feng Z; Ling KK; Karp GM; Qi H; Woll MG; Chen G; Zhang N; Gabbeta V; Vazirani P; Bhattacharyya A; Furia B; Risher N; Sheedy J; Kong R; Ma J; Turpoff A; Lee CS; Zhang X; Moon YC; Trifillis P; Welch EM; Colacino JM; Babiak J; Almstead NG; Peltz SW; Eng LA; Chen KS; Mull JL; Lynes MS; Rubin LL; Fontoura P; Santarelli L; Haehnke D; McCarthy KD; Schmucki R; Ebeling M; Sivaramakrishnan M; Ko CP; Paushkin SV; Ratni H; Gerlach I; Ghosh A; Metzger F
Science; 2014 Aug; 345(6197):688-93. PubMed ID: 25104390
[TBL] [Abstract][Full Text] [Related]
3. 5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells.
Yuo CY; Lin HH; Chang YS; Yang WK; Chang JG
Ann Neurol; 2008 Jan; 63(1):26-34. PubMed ID: 17924536
[TBL] [Abstract][Full Text] [Related]
4. The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.
Kletzl H; Marquet A; Günther A; Tang W; Heuberger J; Groeneveld GJ; Birkhoff W; Mercuri E; Lochmüller H; Wood C; Fischer D; Gerlach I; Heinig K; Bugawan T; Dziadek S; Kinch R; Czech C; Khwaja O
Neuromuscul Disord; 2019 Jan; 29(1):21-29. PubMed ID: 30553700
[TBL] [Abstract][Full Text] [Related]
5. A SMN2 Splicing Modifier Rescues the Disease Phenotypes in an In Vitro Human Spinal Muscular Atrophy Model.
Son YS; Choi K; Lee H; Kwon O; Jung KB; Cho S; Baek J; Son B; Kang SM; Kang M; Yoon J; Shen H; Lee S; Oh JH; Lee HA; Lee MO; Cho HS; Jung CR; Kim J; Cho S; Son MY
Stem Cells Dev; 2019 Apr; 28(7):438-453. PubMed ID: 30667343
[TBL] [Abstract][Full Text] [Related]
6. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy.
Williams JH; Schray RC; Patterson CA; Ayitey SO; Tallent MK; Lutz GJ
J Neurosci; 2009 Jun; 29(24):7633-8. PubMed ID: 19535574
[TBL] [Abstract][Full Text] [Related]
7. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.
Hua Y; Sahashi K; Rigo F; Hung G; Horev G; Bennett CF; Krainer AR
Nature; 2011 Oct; 478(7367):123-6. PubMed ID: 21979052
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of an SMN2-based intermediate mouse model of Spinal Muscular Atrophy.
Cobb MS; Rose FF; Rindt H; Glascock JJ; Shababi M; Miller MR; Osman EY; Yen PF; Garcia ML; Martin BR; Wetz MJ; Mazzasette C; Feng Z; Ko CP; Lorson CL
Hum Mol Genet; 2013 May; 22(9):1843-55. PubMed ID: 23390132
[TBL] [Abstract][Full Text] [Related]
9. Securinine enhances SMN2 exon 7 inclusion in spinal muscular atrophy cells.
Chen YC; Chang JG; Liu TY; Jong YJ; Cheng WL; Yuo CY
Biomed Pharmacother; 2017 Apr; 88():708-714. PubMed ID: 28152480
[TBL] [Abstract][Full Text] [Related]
10. Specific Correction of Alternative Survival Motor Neuron 2 Splicing by Small Molecules: Discovery of a Potential Novel Medicine To Treat Spinal Muscular Atrophy.
Ratni H; Karp GM; Weetall M; Naryshkin NA; Paushkin SV; Chen KS; McCarthy KD; Qi H; Turpoff A; Woll MG; Zhang X; Zhang N; Yang T; Dakka A; Vazirani P; Zhao X; Pinard E; Green L; David-Pierson P; Tuerck D; Poirier A; Muster W; Kirchner S; Mueller L; Gerlach I; Metzger F
J Med Chem; 2016 Jul; 59(13):6086-100. PubMed ID: 27299419
[TBL] [Abstract][Full Text] [Related]
11. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs.
Poirier A; Weetall M; Heinig K; Bucheli F; Schoenlein K; Alsenz J; Bassett S; Ullah M; Senn C; Ratni H; Naryshkin N; Paushkin S; Mueller L
Pharmacol Res Perspect; 2018 Dec; 6(6):e00447. PubMed ID: 30519476
[TBL] [Abstract][Full Text] [Related]
12. Improvement of spinal muscular atrophy via correction of the SMN2 splicing defect by Brucea javanica (L.) Merr. extract and Bruceine D.
Baek J; Jeong H; Ham Y; Jo YH; Choi M; Kang M; Son B; Choi S; Ryu HW; Kim J; Shen H; Sydara K; Lee SW; Kim SY; Han SB; Oh SR; Cho S
Phytomedicine; 2019 Dec; 65():153089. PubMed ID: 31563042
[TBL] [Abstract][Full Text] [Related]
13. SMN deficiency alters Nrxn2 expression and splicing in zebrafish and mouse models of spinal muscular atrophy.
See K; Yadav P; Giegerich M; Cheong PS; Graf M; Vyas H; Lee SG; Mathavan S; Fischer U; Sendtner M; Winkler C
Hum Mol Genet; 2014 Apr; 23(7):1754-70. PubMed ID: 24218366
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia is a modifier of SMN2 splicing and disease severity in a severe SMA mouse model.
Bebee TW; Dominguez CE; Samadzadeh-Tarighat S; Akehurst KL; Chandler DS
Hum Mol Genet; 2012 Oct; 21(19):4301-13. PubMed ID: 22763238
[TBL] [Abstract][Full Text] [Related]
15. Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy.
Shababi M; Glascock J; Lorson CL
Hum Gene Ther; 2011 Feb; 22(2):135-44. PubMed ID: 20804424
[TBL] [Abstract][Full Text] [Related]
16. Discovery and Optimization of Small Molecule Splicing Modifiers of Survival Motor Neuron 2 as a Treatment for Spinal Muscular Atrophy.
Woll MG; Qi H; Turpoff A; Zhang N; Zhang X; Chen G; Li C; Huang S; Yang T; Moon YC; Lee CS; Choi S; Almstead NG; Naryshkin NA; Dakka A; Narasimhan J; Gabbeta V; Welch E; Zhao X; Risher N; Sheedy J; Weetall M; Karp GM
J Med Chem; 2016 Jul; 59(13):6070-85. PubMed ID: 27299569
[TBL] [Abstract][Full Text] [Related]
17. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.
Riessland M; Ackermann B; Förster A; Jakubik M; Hauke J; Garbes L; Fritzsche I; Mende Y; Blumcke I; Hahnen E; Wirth B
Hum Mol Genet; 2010 Apr; 19(8):1492-506. PubMed ID: 20097677
[TBL] [Abstract][Full Text] [Related]
18. Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy.
Groen EJN; Perenthaler E; Courtney NL; Jordan CY; Shorrock HK; van der Hoorn D; Huang YT; Murray LM; Viero G; Gillingwater TH
Hum Mol Genet; 2018 Aug; 27(16):2851-2862. PubMed ID: 29790918
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
[TBL] [Abstract][Full Text] [Related]
20. A humanized Smn gene containing the SMN2 nucleotide alteration in exon 7 mimics SMN2 splicing and the SMA disease phenotype.
Gladman JT; Bebee TW; Edwards C; Wang X; Sahenk Z; Rich MM; Chandler DS
Hum Mol Genet; 2010 Nov; 19(21):4239-52. PubMed ID: 20705738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
